Mark Cuban Cost Plus Drug Company confers savings on urologic drugs

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.

In this video, Ruchika Talwar, MD, discusses the background and notable findings from the Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.